Trials / Completed
CompletedNCT03047031
Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis. The safety of nintedanib has been assessed in clinical trials.This active surveillance aims to collect the safety data of 200 IPF patients treated with nintedanib in approved indication after the commercial availability of the drug in India (23rd January 2017). The objective is to look at safety of nintedanib in the real world setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nintedanib | Nintedanib |
| DRUG | Pirfenidone | Pirfenidone |
Timeline
- Start date
- 2017-04-05
- Primary completion
- 2022-07-21
- Completion
- 2022-07-21
- First posted
- 2017-02-08
- Last updated
- 2025-05-16
- Results posted
- 2024-08-22
Locations
8 sites across 1 country: India
Source: ClinicalTrials.gov record NCT03047031. Inclusion in this directory is not an endorsement.